AG-825 (20 mg/kg, i.p.) decreases peritoneal inflammation in Zymosan (HY-159069)-treated mice, and increases lung neutrophil apoptosis and macrophage efferocytosis in a murine acute lung injury model[4].
AG-825 (1 mg/kg, min-osmotic pump, 14 days) causes cardiac dilation and selective increase in β1AR density in mice[7].
| Animal Model: | Murine model of LPS induced acute lung inflammation[4] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Had no effect on percentage of, or absolute number of neutrophils or macrophages.
Increased the percentage of neutrophil apoptosis.
Elevated macrophage efferocytosis.
|
| Animal Model: | Murine model of Zymosan (HY-159069)-induced peritonitis[4] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Did not induce leukopenia.
Showed fewer inflammatory cells in peritoneal lavage.
Reduced the neutrophil chemoattractant and proinflammatory cytokine, KC.
Reduced IgM.
|
